LL-37 (17-29) [R23L]

General Information


DRACP ID  DRACP02875

Peptide Name   LL-37 (17-29) [R23L]

Sequence  FKRIVQLIKDFLR

Sequence Length  13

UniProt ID  P49913 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=18.9 μg/ml MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: HC50=114 µg/ml

Normal (non-cancerous) Cytotoxicity  DLF lung fibroblasts: IC50=23.5 μg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02875

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C80H134N22O17

Absent amino acids  ACEGHMNPSTWY

Common amino acids  FIKLR

Mass  189031

Pl  11.65

Basic residues  4

Acidic residues  1

Hydrophobic residues  7

Net charge  3

Boman Index  -2552

Hydrophobicity  20

Aliphatic Index  142.31

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32567085

Title  Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents

Doi 10.1002/psc.3254

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_17793

DRACP is developed by Dr.Zheng's team.